Health Check: Actinogen awaits crucial futility ruling on Alzheimer's disease trial
This Stockhead article discusses the upcoming futility analysis for Actinogen Medical’s Phase IIb/III XanaMIA trial evaluating Xanamem as a potential treatment for Alzheimer’s disease.
Read the full article here: https://stockhead.com.au/health/health-check-actinogen-awaits-crucial-futility-ruling-on-alzheimers-disease-trial/
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Actinogen. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Actinogen a question about this update.